You are here: Industry Insights > COVID-19

News List

Feinstein Institutes gets $11.3 million subcontract for COVID-19 antibody research expresspharma
November 06, 2020
Researchers to develop and deploy serological (antibody) testing assays as well as study the molecular mechanisms driving serological, humoral, and cellular immune responses to the virus.
Scientists develop COVID-19 vaccine candidate that generates very high neutralising antibodies expresspharma
November 06, 2020
The study finds that the nanoparticle vaccine generates ten times more protective antibodies in mice, even at a six-fold lower vaccine dose, and also shows a strong B-cell immune response after administration.
AIIMS study finds ivermectin prophylaxis reduces infection in Covid-19 patients pharmaceutical-technology
November 06, 2020
A study by All India Institutes of Medical Sciences (AIIMS)-Bhubaneswar in the Indian state of Odisha has found that two doses of potential drug ivermectin prophylaxis resulted in a 73% reduction in Covid-19 infection.
Humanigen to enter Asia-Pacific market with Covid-19 drug pharmaceutical-technology
November 06, 2020
Humanigen has executed a licensing agreement with Telcon RF Pharmaceutical and KPM Tech for development and commercialisation rights of its Covid-19 drug lenzilumab for South Korea and the Philippines.
Common osteoporosis treatments could reduce incidence of COVID-19 europeanpharmaceuticalreview
November 06, 2020
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
Cancer treatment could be replicated for COVID-19 worldpharmanews
November 06, 2020
Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists.
Scientists identify synthetic mini-antibody to combat COVID-19 worldpharmanews
November 06, 2020
The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine worldpharmanews
November 06, 2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 ...
TCM Lianhua Qingwen's Access to Russian Market Marks Its Global Expansion prnasia
November 06, 2020
Yiling Pharmaceutical discloses that it has received the Certificate of Registration for Dietary Supplements approved and issued by the authorized agency of Eurasian Economic Union, which indicates that the company's patent drug Lianhua Qingwen Capsule ..
Equine polyclonal antibodies have shown higher potency in in-vitro studies of SARS-CoV-2 virus neutralisation expresspharma
November 05, 2020
Bharat Serums and Vaccines has initiated a research project to co-develop an equine polyclonal antibody, alongwith NIV, against COVID-19.